title: Adjuvants: present regulatory challenges.
abstract: Research on new adjuvants and delivery systems has expanded dramatically in the last decade. New generation vaccines, based on recombinant proteins, synthetics, and conjugated antigens have emerged but they have limitations because of their poor immunogenic properties, and therefore more cooperative adjuvants for the promotion of the immune response are required. Different molecules have been screened for their ability to enhance the immune response to vaccine antigens, e.g. liposomes, protein cochleate formulations, ISCOMs and cytokines, to name the few. However, most of the vaccines that are currently licensed use aluminum salts or calcium phosphate.
authors.affiliation: Biological Department, State Control Center for the Quality of Drugs (CECMED), 200 Street No. 1706, P.O. Box 16065, CP 11600 Havana, Cuba. danay@cecmed.sld.cu
authors.forename: Danay Mora
authors.initials: DM
authors.lastname: Pascual
authors.forename: Rolando Dominguez
authors.initials: RD
authors.lastname: Morales
authors.forename: Erich Duque
authors.initials: ED
authors.lastname: Gil
authors.forename: Lázara Martínez
authors.initials: LM
authors.lastname: Muñoz
authors.forename: Juliette Escoto
authors.initials: JE
authors.lastname: López
authors.forename: Olga L Jacobo
authors.initials: OL
authors.lastname: Casanueva
mesh_terms: D000276:Adjuvants, Immunologic / Q000009:adverse effects* / Q000494:pharmacology*; D017277:Drug Approval; D016503:Drug Delivery Systems / Q000009:adverse effects; D004335:Drug and Narcotic Control; D017408:Guidelines as Topic
chemical_list: D000276:Adjuvants, Immunologic